title: Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.
abstract: A panel of paired primary virus isolates and envelope pseudoviruses from sixty strains representing six HIV-1 clades was tested for neutralization using pooled, clade-specific plasma in two prominently utilized neutralization platforms: a primary isolate assay using peripheral blood mononuclear cells (PBMC) and a pseudovirus assay using a reporter epithelial cell line. Using the PMBC assay, pairing of the antibody pool against homologous clade viruses generated the highest geometric mean neutralizing antibody titer in 4 out of 6 clades tested, and neutralization patterns showed numerous examples of reciprocal cross-recognition between antibody and viruses of specific clade pairs. In the pseudovirus assay, cross-clade neutralization was more limited, with fewer distinct cross-clade relationships evident. The clade C antibody pool was broadly cross-reactive, neutralizing the greatest number of viruses in both assays. These data highlight the importance of the neutralization assay format employed and suggest that clade C envelopes merit further evaluation for the elicitation of broadly neutralizing antibodies.
authors.affiliation: Henry M Jackson Foundation, Rockville, MD, USA.
authors.forename: Bruce K
authors.initials: BK
authors.lastname: Brown
authors.forename: Lindsay
authors.initials: L
authors.lastname: Wieczorek
authors.forename: Eric
authors.initials: E
authors.lastname: Sanders-Buell
authors.forename: Andrew
authors.initials: A
authors.lastname: Rosa Borges
authors.forename: Merlin L
authors.initials: ML
authors.lastname: Robb
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Birx
authors.forename: Nelson L
authors.initials: NL
authors.lastname: Michael
authors.forename: Francine E
authors.initials: FE
authors.lastname: McCutchan
authors.forename: Victoria R
authors.initials: VR
authors.lastname: Polonis
mesh_terms: D016915:AIDS Vaccines / Q000276:immunology*; D000918:Antibody Specificity; D002478:Cells, Cultured; D003429:Cross Reactions; D004196:Disease Outbreaks; D015483:HIV Antibodies / Q000097:blood / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control; D015497:HIV-1 / Q000145:classification / Q000276:immunology*; D006367:HeLa Cells; D006801:Humans; D007963:Leukocytes, Mononuclear; D009500:Neutralization Tests / Q000379:methods* / Q000592:standards; D012680:Sensitivity and Specificity
chemical_list: D016915:AIDS Vaccines; D015483:HIV Antibodies